Oramed Pharmaceuticals Inc. Announces The Completion Of Its World Renowned Scientific Board
JERUSALEM, Feb. 22 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals Inc. is pleased to announce the completion of the Scientific Board. CEO Nadav Kidron states, "We have been honoured with the presence of a select few, highly influential individuals in fields of diabetes, immunology, and endocrinology. All four of our new members have contributed to these fields extensively over the past decades, and carry respectable positions in many of the organizations guiding diabetic treatment and awareness globally."
The members of our board are strong iconic figures in various regions globally. Dr. Barzilai has had a strong career in diabetes studies between Israel, London and the United States. He has worked for such esteemed institutions as Hadassah Research Hospital, NIH (National Institute of Health), and many esteemed US based university hospitals including Cornell and Yale.
Prof. Ele Ferrannini is well known globally for his work in diabetes, has been a past President of the EASD (European Association for the Study of Diabetes), and has been recognized as a "highly cited scientists." (ISIhighlycited.com).
Derek LeRoith, MD, PhD achieved his successes predominantly in the United States and South Africa, contributing research and data leading to over 500 publications. He comes to us with a large list of awards including but are not limited to, Medal for Physiology, the Bronte Stewart Award for PhD Thesis, British Endocrine Society Transatlantic Medal, and multiple Memorial Lectures. In addition, Dr. LeRoith has strong connections with the American Diabetes Association and other major health organizations in the United States.
Last, but not least, Itamar Raz, M.D. has come on our board. He is a professor of Internal Medicine at Hadassah University Medical Center and the head of the Diabetes Unit at Hadassah. He has been a strong figure for Diabetes in Israel as the head of the Israel National Council of Diabetes and president of D-Cure, a foundation that supports research in the field of diabetes.
This advisory board is expected to help support our investigation of oncoming technology, including the conversion of other hormones, proteins, and vaccinations, which at present are injected, to oral gel capsules. As well the board is hoped to help further along the present trials with the oral insulin and the flu vaccine, which still is undergoing pre- clinical trials.
About Oramed Pharmaceuticals, Inc:
Oramed Pharmaceuticals' is an Israeli based company focused on the development of oral delivery solutions based on proprietary technology. Diabetes is one of the most rapidly growing diseases in the world and is one that requires constant and often unpleasant monitoring and drug therapy regimen. Oramed is currently developing an orally soft gel insulin capsule for the treatment of diabetes. The Company is also pursuing the development of oral delivery solutions for other drugs and vaccines. For more information on Oramed Pharmaceuticals please visit our website: http://www.oramedpharma.com
Legal Notice Regarding Forward Looking Statements
This news release contains statements, which may constitute "forward-looking statements". Those statements include statements regarding the intent, belief or current expectations of Oramed Pharmaceutical Inc., and members of our management as well as the assumptions on which such statements are based. Forward-looking statements in this release include: that we are currently developing an orally ingestible soft gel insulin capsule for the treatment of diabetes and for other diseases; that our advisory board is expected to help support our investigation of oncoming technology and to help further along the present trials with the oral insulin and the flu vaccine. Factors which may significantly change or prevent our forward looking statements from fruition include that oral insulin gel capsules may not be suitable for our intended purposes; our advisory board members may not devote sufficient time or effort to make a difference, or may not stay on the advisory board; we may be unsuccessful in developing any products; we may be unable to raise funds and resources to pursue research and development; we may be unable to successfully defend our patents from infringement by third parties, there is a risk that our patents may be subsequently shown to be invalid or infringe the patents of others, our products may never gain FDA or other regulatory body approval for human consumption and we may be unable to successfully commercialize our future products. Readers should refer to our most recent 10-KSB filed on Edgar for more detailed risk factors.
Investor Relations Contact: Oramed Pharmaceuticals, Inc. Vinisha Agnihotri (646) 467-2252 info@oramedpharma.comhttp://www.oramedpharma.com
Oramed Pharmaceuticals Inc.CONTACT: Vinisha Agnihotri of Oramed Pharmaceuticals, Inc.,+1-646-467-2252, info@oramedpharma.com
Web site: http://www.oramedpharma.com//